AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26141682 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 160
Study 26141682 — intervention group
Group type: EXPERIMENTAL
Intervention: Body warming
Number of subjects: 160
Study 26141682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 23222967 — intervention group
Group type: EXPERIMENTAL
Intervention: Paula method (12 private lessons)
Number of subjects: 143
Study 23222967 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) (6 group lessons)
Number of subjects: 143
Study 23222967 — intervention group
Group type: EXPERIMENTAL
Intervention: Paula method
Number of subjects: 143
Study 23222967 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 143
Study 21239142 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Review Intervention for Monitoring and Evaluating sites (PRIME)
Number of subjects: 8
Study 18456558 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 720
Study 18456558 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 720
Study 16947627 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate (MTX)
Number of subjects: 520
Study 16947627 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 520
Study 12929019 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl obliteration (group A, n = 21)
Number of subjects: 41
Study 12929019 — intervention group
Group type: COMPARATOR
Intervention: Propranolol administration (group B, n = 20)
Number of subjects: 41
Study 10720043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg and 180 mg or 120 mg and 240 mg)
Number of subjects: 24
Study 10720043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 24
Study 10720043 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide
Number of subjects: 24
Study 8912778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 102
Study 8912778 — intervention group
Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV)
Number of subjects: 102
Study 8912778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation parameters (peak airway pressure, mean airway pressure, tidal volume)
Number of subjects: 102
Study 8912778 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall degree of air space disease
Number of subjects: 102
Study 1547045 — intervention group
Group type: COMPARATOR
Intervention: 0.375% bupivacaine 10 ml alone
Number of subjects: 30
Study 1547045 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine 10 ml combined with fentanyl 100 micrograms
Number of subjects: 30
Study 4087369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion at 2 ml/min (Group A)
Number of subjects: 40
Study 4087369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion at 5 ml/min (Group B)
Number of subjects: 40
Study 4087369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion at 10 ml/min (Group C)
Number of subjects: 40
Study 4087369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion at 5 ml/min with 40 mg furosemide (Group D)
Number of subjects: 40
Study 29846530 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab 150 mg every 2 weeks (Q2W)
Number of subjects: 187
Study 29846530 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab 150 mg weekly (QW)
Number of subjects: 187
Study 29846530 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab 300 mg weekly (QW)
Number of subjects: 187
Study 29846530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 27515515 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release melatonin (3 mg) administered daily at 21:00 ± 1 h from day 1 to day 28 of admission
Number of subjects: 0
Study 27515515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25038509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated toothpaste
Number of subjects: 15
Study 25038509 — intervention group
Group type: EXPERIMENTAL
Intervention: SnCl2/AmF/NaF mouthrinse
Number of subjects: 15
Study 25038509 — intervention group
Group type: COMPARATOR
Intervention: Negative control (non-fluoridated toothpaste)
Number of subjects: 15
Study 25038509 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk and CPP-ACP pastes (with or without fluoride)
Number of subjects: 15
Study 22173265 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 72
Study 22173265 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 21203698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (830 nm, 15 mW, 12 J/cm²) daily from the 1st day until the end of RT for 5 consecutive days
Number of subjects: 25
Study 21203698 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide (AH) 310 mg/5 mL, 4 times/day throughout the duration of RT
Number of subjects: 25
Study 18055958 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of reattribution training
Number of subjects: 141
Study 18055958 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 141
Study 14667696 — intervention group
Group type: EXPERIMENTAL
Intervention: Living kind concepts at different hierarchical levels (e.g. tree, oak)
Number of subjects: 3
Study 14667696 — intervention group
Group type: EXPERIMENTAL
Intervention: Artifact concepts at different hierarchical levels
Number of subjects: 3
Study 14667696 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults' beliefs about within‐category similarity for concepts at different levels
Number of subjects: 3
Study 11697755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (2 mg)
Number of subjects: 11
Study 11697755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (2 mg)
Number of subjects: 11
Study 11697755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lorazepam (2 mg)
Number of subjects: 11
Study 11697755 — intervention group
Group type: EXPERIMENTAL
Intervention: All routes (Intranasal, Intravenous, Intramuscular)
Number of subjects: 11
Study 9068685 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 0
Study 8180641 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine (0.5 mL, intramuscularly)
Number of subjects: 172
Study 8180641 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 172
Study 8180641 — intervention group
Group type: COMPARATOR
Intervention: DTwP vaccine (0.5 mL, intramuscularly)
Number of subjects: 172
Study 8180641 — intervention group
Group type: COMPARATOR
Intervention: DTwP vaccine
Number of subjects: 172
Study 8180641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DTaP and DTwP vaccines
Number of subjects: 172
Study 3282463 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate 200 mg/m2 body surface area for 5 days by continuous intravenous infusion
Number of subjects: 164
Study 3282463 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin 8 IU/kg body weight every 6 hours for 5 days by intramuscular injection
Number of subjects: 164
Study 28929258 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin (5-HT) administered via intraventricular injection
Number of subjects: 0
Study 28929258 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA) administered via intraventricular injection
Number of subjects: 0
Study 26659927 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of terlipressin (TERLI-INF group) at an initial dose of 2 mg/day
Number of subjects: 78
Study 26659927 — intervention group
Group type: COMPARATOR
Intervention: Intravenous boluses of terlipressin (TERLI-BOL group) at an initial dose of 0.5 mg every 4 hours
Number of subjects: 78
Study 26659927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TERLI-INF and TERLI-BOL)
Number of subjects: 78
Study 26659927 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of terlipressin (TERLI-INF group)
Number of subjects: 78
Study 26659927 — intervention group
Group type: COMPARATOR
Intervention: Intravenous boluses of terlipressin (TERLI-BOL group)
Number of subjects: 78
Study 24621203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss(®) Collagen
Number of subjects: 28
Study 24621203 — intervention group
Group type: COMPARATOR
Intervention: No grafting (Control)
Number of subjects: 28
Study 23586518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cradle hold position
Number of subjects: 25
Study 23586518 — intervention group
Group type: COMPARATOR
Intervention: Side lying position
Number of subjects: 25
Study 20350430 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual drug withdrawal after a 12-week treatment course
Number of subjects: 97
Study 20350430 — intervention group
Group type: COMPARATOR
Intervention: Immediate drug withdrawal
Number of subjects: 97
Study 18444136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 0
Study 18444136 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study 18444136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and selenium
Number of subjects: 0
Study 18444136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16766604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder procedure
Number of subjects: 6822
Study 16766604 — intervention group
Group type: COMPARATOR
Intervention: No reminder procedure
Number of subjects: 6822
Study 14650707 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg enalapril tablets (test product)
Number of subjects: 14
Study 14650707 — intervention group
Group type: COMPARATOR
Intervention: 20-mg enalapril tablets (reference product)
Number of subjects: 14
Study 10871571 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (treadmill walking to 1.8 times resting metabolic rate)
Number of subjects: 6
Study 10871571 — intervention group
Group type: COMPARATOR
Intervention: Sedentary conditions (1.4 times resting metabolic rate)
Number of subjects: 6
Study 10871571 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 6
Study 10871571 — intervention group
Group type: COMPARATOR
Intervention: Sedentary conditions
Number of subjects: 6
Study 9170118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (Natil, 1,600 mg/day)
Number of subjects: 139
Study 9170118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 1313163 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + glucomannan (approx. 4 g/die in 3 doses)
Number of subjects: 50
Study 1313163 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet therapy alone
Number of subjects: 50
Study 6732250 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 50
Study 6732250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Misonidazole)
Number of subjects: 50
Study 31204473 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Hydroxybenzo[a]pyrene glucuronide (BaP-3-G)
Number of subjects: 150
Study 31204473 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Hydroxybenzo[a]pyrene sulfate (BaP-3-S)
Number of subjects: 150
Study 31204473 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary 3-OHBaP conjugates
Number of subjects: 150
Study 29048708 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus propofol (MP)
Number of subjects: 120
Study 29048708 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 120
Study 26657945 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a Diabetes Prevention Program (DPP)‐derived lifestyle intervention including mailed gestational weight gain recommendations and 13 telephone sessions between 6 weeks and 6 months postpartum.
Number of subjects: 2280
Study 26657945 — intervention group
Group type: COMPARATOR
Intervention: Usual care (mailed recommendations only).
Number of subjects: 2280
Study 26657945 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a Diabetes Prevention Program (DPP)‐derived lifestyle intervention.
Number of subjects: 2280
Study 24643281 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 731
Study 24643281 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 731
Study 23588462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (40% carbohydrate/30% protein/30% fat)
Number of subjects: 40
Study 23588462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (55% carbohydrate/15% protein/30% fat)
Number of subjects: 40
Study 23588462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A
Number of subjects: 40
Study 23588462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B
Number of subjects: 40
Study 20157316 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 6916
Study 20157316 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivity
Number of subjects: 6916
Study 17585375 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 0.5% timolol maleate
Number of subjects: 184
Study 17585375 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 184
Study 15867584 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 0
Study 15867584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12488198 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalized training sessions in clinical breast examination
Number of subjects: 0
Study 12488198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formalized training)
Number of subjects: 0
Study 10219865 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 1962
Study 7887637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 7887637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy followed by chest irradiation
Number of subjects: 0
Study 7887637 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy in combination with chemotherapy
Number of subjects: 0
Study 7887637 — intervention group
Group type: COMPARATOR
Intervention: Alternating chemotherapy
Number of subjects: 0
Study 7887637 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy (increased dose intensity)
Number of subjects: 0
Study 7887637 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs (CPT-11, taxol, axotere, vinorelbine, gemcitabine)
Number of subjects: 0
Study 1919301 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 54
Study 1919301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 1919301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron absorption
Number of subjects: 54
Study 6228015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 6228015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30819228 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (reminder via cellphone text message/call or bottle-based flash/alarm, plus monthly counseling)
Number of subjects: 80
Study 30819228 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard counseling at routine monthly clinic visits)
Number of subjects: 80
Study 29291768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothering from the Inside Out (MIO) treatment
Number of subjects: 84
Study 27568506 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation intervention combined with tele-health medication clinic for nicotine replacement therapy (NRT)
Number of subjects: 413
Study 27568506 — intervention group
Group type: COMPARATOR
Intervention: Referral to VA specialty smoking cessation care (control)
Number of subjects: 413
Study 25306746 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaltea goat's milk 200 ml/day during basic therapy
Number of subjects: 90
Study 25306746 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies and multistrain RioFlora Balance probiotics in addition to goat's milk
Number of subjects: 90
Study 25306746 — intervention group
Group type: COMPARATOR
Intervention: Traditional basic dietary therapy
Number of subjects: 90
Study 22068288 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening information plus patient activation and barriers counseling
Number of subjects: 270
Study 22068288 — intervention group
Group type: COMPARATOR
Intervention: CRC screening information
Number of subjects: 270
Study 20153029 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler)
Number of subjects: 0
Study 17389558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg
Number of subjects: 2
Study 17389558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 16685046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic low-carbohydrate diet (KLC)
Number of subjects: 20
Study 16685046 — intervention group
Group type: COMPARATOR
Intervention: Nonketogenic low-carbohydrate diet (NLC)
Number of subjects: 20
Study 16685046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both KLC and NLC diets
Number of subjects: 20
Study 15459602 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2000 mg/dose, n = 95
Number of subjects: 180
Study 15459602 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 85
Number of subjects: 180
Study 15459602 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 180
Study 15459602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 10937408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B education/promotion curriculum package; administered over 4 class periods before vaccination.
Number of subjects: 15811
Study 10937408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned);
Number of subjects: 15811
Study 8745328 — intervention group
Group type: EXPERIMENTAL
Intervention: bilayered cultured skin equivalent (Graftskin)
Number of subjects: 233
Study 1569973 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus plasmapheresis
Number of subjects: 86
Study 1569973 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (prednisone and cyclophosphamide)
Number of subjects: 86
Study 3865246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg DEX (dexamethasone) administered at 2300 h
Number of subjects: 40
Study 3865246 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg DEX (dexamethasone) administered at 2300 h
Number of subjects: 40
Study 30484332 — intervention group
Group type: EXPERIMENTAL
Intervention: US‐TAP block with 20 mL of 0.35% ropivacaine
Number of subjects: 100
Study 30484332 — intervention group
Group type: COMPARATOR
Intervention: No US‐TAP block
Number of subjects: 100
Study 27511476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/candesartan combinations
Number of subjects: 1801
Study 27511476 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS (N) monotherapy
Number of subjects: 1801
Study 27511476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1801
Study 25527666 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-infected infants
Number of subjects: 1201
Study 25527666 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-exposed infants
Number of subjects: 1201
Study 25527666 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations <10 ng/mL for HIV-infected infants
Number of subjects: 1201
Study 25527666 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations <10 ng/mL for HIV-exposed infants
Number of subjects: 1201
Study 22812593 — intervention group
Group type: EXPERIMENTAL
Intervention: New moisturizer (CRM) containing a ceramide precursor applied for 27 days
Number of subjects: 0
Study 22812593 — intervention group
Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 0
Study 21655990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg o.d. for 1 week, then 1 g b.d. for 1 week)
Number of subjects: 55
Study 21655990 — intervention group
Group type: COMPARATOR
Intervention: Internal control (no treatment for 1 week)
Number of subjects: 55
Study 21655990 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 55
Study 21655990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (same dose regimen as above)
Number of subjects: 55
Study 18708686 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+Pro (7.75% carbohydrate / 1.94% protein)
Number of subjects: 11
Study 18708686 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+CHO (9.69% carbohydrate)
Number of subjects: 11
Study 18708686 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 11
Study 18708686 — intervention group
Group type: COMPARATOR
Intervention: CHO (7.75% carbohydrate)
Number of subjects: 11
Study 17002808 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-item symptom index based on FACT-BRM scale
Number of subjects: 209
Study 14601275 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg propofol (group A)
Number of subjects: 121
Study 14601275 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg propofol (group B)
Number of subjects: 121
Study 14601275 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/kg propofol (test-dose)
Number of subjects: 121
Study 14601275 — intervention group
Group type: COMPARATOR
Intervention: Control value (baseline)
Number of subjects: 121
Study 14601275 — intervention group
Group type: COMPARATOR
Intervention: Correlation between test-dose and induction-dose
Number of subjects: 121
Study 10854683 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isradipine plus 5 mg enalapril
Number of subjects: 102
Study 10854683 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 102